Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche to acquire immuno-oncology company Tusk Therapeutics

Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.

Read More »

Walgreens to pay $34.5 million to settle U.S. charges of misleading investors

Walgreens Boots Alliance Inc. will pay $34.5 million to settle charges that the company misled investors about the increased risk of missing a key financial goal related to its merger in 2012, the top U.S. securities regulator said.

Read More »

Novo Nordisk to cut 250 jobs in the United States

Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.

Read More »

Novartis strikes deal with Chinese firm to make Kymriah

Chinese manufacturer Cellular Biomedicine has been enlisted to make Novartis’ $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world’s most populous country.

Read More »

Lilly Licenses Chugai Pharma’s Oral Diabetes Drug for $50 Million Upfront

Eli Lilly signed a licensing deal for Chugai Pharmaceutical’s oral non-peptidic GLP-1 receptor agonist OWL833.

Read More »

J&J Terminates Imetelstat Collaboration with Geron

Johnson & Johnson and Geron had teamed up to develop and commercialize imetelstat, a first-in-class telomerase inhibitor, for myelofibrosis and myelodysplastic syndromes.

Read More »

U.S. and Cuba Biopharma Venture Sees Fruit in Lung Cancer Study

A Cuban-developed lung cancer treatment combined with Bristol-Myers Squibb’s anti-PDL1 Opdivo shows promise in treating patients who would not likely benefit from immune checkpoint inhibition.

Read More »

Lyra Therapeutics Announces $29.5 Million Series B Financing to Advance Innovative Therapeutics for Ear, Nose and Throat Diseases

Lyra Therapeutics Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced a $29.5 million Series B equity financing.

Read More »

Alexion to obtain Syntimmune

Alexion Pharmaceuticals is acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn), for a total value of up to $1.2 billion.

Read More »

Indivior slashes 2018 revenue outlook for Sublocade

Indivior Plc slashed full-year 2018 revenue expectation for the injectable opioid addiction drug Sublocade, sending the company’s shares tumbling more than 16 percent.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom